Teva Pharma (TEVA) PT Lowered to $64 at Mizuho; 'Buy' Maintained
- Top 10 News for 12/2: Crude Rips on OPEC Cut; Starbucks' Schultz Steps Down; Nonfarm Payrolls Flat in Nov.
- Unemployment Rate Drops to 4.6%
- Bond yields slip on U.S. jobs data, euro steady before Italy vote
- Alibaba (BABA) Founder Jack Ma Discuss Plans to Retire; 'I Don't Want to Die at the Office'
- Starbucks Coffee (SBUX) CEO Howard Schultz to Step Down, Appointed Executive Chairman; Kevin Johnson New CEO
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Mizuho Securities analyst Irina Koffler lowered her price target on Teva Pharma (NYSE: TEVA) price to $64.00 (from $70.00) following a negative IPR decision on two Copaxone patents but maintained a Buy rating. The analyst has gotten more conservative in their outer year expectations.
Koffler commented, "Our Buy thesis is predicated on valuation rather than any particular catalyst, though additional visibility into the recently acquired generics business and pipeline could serve to drive share momentum in 2H:16."
Shares of Teva Pharma closed at $51.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva Pharma (TEVA) Loses Bid to Revive '413, '250, and Third Capaxone Patent in IPR Review - Bloomberg
- Mizuho Securities Adjusts Estimates Following Gap, Inc. (GPS) Comp Miss
- Brean Capital Cuts Price Target on G-III Apparel Group (GIII) Following 3Q Miss
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesIrina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!